Annexon, Inc.
Annexon, Inc. (Nasdaq: ANNX) is a clinical-stage biopharmaceutical company developing targeted immunotherapies for diseases associated with abnormal activation of the classical complement pathway. Its product candidates aim to inhibit C1q or related pathway components in autoimmune, neurodegenerative and ophthalmic… From the company’s description.
In fiscal 2025, Annexon, Inc. reported a net loss of $206.69M. Operations used $186.36M in cash.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Annexon, Inc. does
In the company’s own words
Annexon, Inc. (Nasdaq: ANNX) is a clinical-stage biopharmaceutical company developing targeted immunotherapies for diseases associated with abnormal activation of the classical complement pathway. Its product candidates aim to inhibit C1q or related pathway components in autoimmune, neurodegenerative and ophthalmic conditions. Tanruprubart, an investigational antibody, is being developed for Guillain-Barré syndrome, an acute neurological disease; the company filed a European marketing application for the candidate in 2026 and is conducting a study in the United States and Europe. Vonaprument, an investigational C1q inhibitor delivered into the eye, is in Phase 3 development for geographic atrophy, an advanced form of dry age-related macular degeneration. ANX1502 is an oral small molecule being evaluated for autoimmune conditions, including cold agglutinin disease. Other programs include candidates studied in Huntington’s disease, amyotrophic lateral sclerosis and lupus nephritis. Annexon retains worldwide development and commercialization rights to its product candidates, including rights held through exclusive licenses. The company was co-founded by scientist Ben Barres and researcher Arnon Rosenthal.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- BRISBANE, CA
- Fiscal year end
- December
- CIK
- 1528115
- SIC
- 2834
Financial performance, year by year
Fiscal 2020–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Annexon, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Annexon, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Annexon, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Annexon, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Annexon, Inc.'s last four quarterly filings that the numbers alone won't show?”